Moderna, Inc. vs Pfizer, Inc. — Stock Comparison
Q·Score Breakdown
4.2
Underperform
Overall
6.5
Hold
Quality
Health
Growth
Valuation
Sentiment
MRNA
Clean balance sheet with low leverage (0.2× debt-to-equity).
⚠ currently unprofitable (-145% margin).
PFE
Strong profitability with 12% net profit margins.
⚠ analyst sentiment is cautious.
Analyst Consensus
HOLD
Target $41.42 (-12.1%)
19 analysts
HOLD
Target $29.00 (+8.5%)
27 analysts
Fundamentals
MRNA
PFE
—
Trailing P/E
19.7×
-10.0×
Forward P/E
9.5×
-145.2%
Profit Margin
12.4%
-105.8%
Gross Margin
75.8%
-28.9%
ROE
8.9%
-29.8%
Revenue Growth
-1.2%
—
Earnings Growth
—
1.34
Beta
0.39
—
Price / Book
—
$18.7B
Market Cap
$152.0B
$22 – $60
52-Week Range
$22 – $29
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load.